T1	DISO 82 107	síndrome antifosfolípidos
#1	AnnotatorNotes T1	C0085278; Antiphospholipid Syndrome; Disease or Syndrome
T2	PROC 130 178	Ensayo abierto de fase IIA de prueba de concepto
T3	PROC 199 210	tratamiento
#2	AnnotatorNotes T3	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T4	DISO 218 233	manifestaciones
#3	AnnotatorNotes T4	C0037088; Signs and Symptoms; Sign or Symptom
T5	DISO 263 288	Síndrome Antifosfolípidos
#4	AnnotatorNotes T5	C0085278; Antiphospholipid Syndrome; Disease or Syndrome
T6	DISO 312 337	síndrome antifosfolípidos
#5	AnnotatorNotes T6	C0085278; Antiphospholipid Syndrome; Disease or Syndrome
T7	CHEM 378 406	anticuerpos antifosfolípidos
#6	AnnotatorNotes T7	C0162595; Antiphospholipid Antibodies; Amino Acid, Peptide, or Protein · Immunologic Factor
T8	DISO 459 474	manifestaciones
#7	AnnotatorNotes T8	C0037088; Signs and Symptoms; Sign or Symptom
T9	DISO 531 541	nefropatía
#8	AnnotatorNotes T9	C0022658; Kidney Diseases; Disease or Syndrome
T10	DISO 551 569	úlceras en la piel
T11	DISO 572 587	trombocitopenia
#9	AnnotatorNotes T11	C0040034; Thrombocytopenia; Disease or Syndrome
T12	PROC 799 835	consentimiento informado por escrito
#10	AnnotatorNotes T12	C0811741; Obtain informed written consent; Health Care Activity
T13	DISO 1002 1029	lupus eritematoso sistémico
#11	AnnotatorNotes T13	C0024141; Lupus Erythematosus, Systemic; Disease or Syndrome
T14	DISO 1034 1054	esclerosis sistémica
#12	AnnotatorNotes T14	C0036421; Systemic Scleroderma; Disease or Syndrome
T15	DISO 1063 1098	enfermedades autoinmunes sistémicas
T16	DISO 1113 1117	SAFL
#13	AnnotatorNotes T16	C0085278; Antiphospholipid Syndrome; Disease or Syndrome
T17	DISO 1166 1181	trombosis aguda
T18	ANAT 1202 1210	vascular
#14	AnnotatorNotes T18	C0005847; Blood Vessel; Body Part, Organ, or Organ Component | C0042591; Vessel Positions; Body Location or Region
T19	CHEM 1300 1310	medicación
#15	AnnotatorNotes T19	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T20	DISO 1187 1218	acontecimiento vascular adverso
#16	AnnotatorNotes T20	C1558950; Adverse Event Associated with Vascular; Finding
T21	DISO 1340 1364	trastorno de la tiroides
#17	AnnotatorNotes T21	C0040128; Thyroid Diseases; Disease or Syndrome
T22	PROC 1381 1392	tirotropina
#18	AnnotatorNotes T22	C0202230; Thyroid stimulating hormone measurement; Laboratory Procedure
T23	PROC 1394 1397	TSH
#19	AnnotatorNotes T23	C0202230; Thyroid stimulating hormone measurement; Laboratory Procedure
T24	PROC 1401 1415	tiroxina libre
#20	AnnotatorNotes T24	C0202225; T4 free measurement; Laboratory Procedure
T25	PROC 874 888	procedimientos
#21	AnnotatorNotes T25	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure | C0184661; Interventional procedure; Therapeutic or Preventive Procedure
T26	DISO 1451 1475	Enfermedad meningocócica
T27	DISO 1493 1510	Hipersensibilidad
#22	AnnotatorNotes T27	C0020517; Hypersensitivity; Pathologic Function | C0429891; Hypersensitivity finding; Finding
T28	CHEM 1579 1587	ALXN1007
#23	AnnotatorNotes T28	C3900167; Immunoglobulin, Anti-(human complement C5a) (human-mus musculus ALXN1007 heavy chain), Disulfide with Human-mus Musculus ALXN1007 Kappa-chain, Dimer; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T29	CHEM 1564 1575	excipientes
#24	AnnotatorNotes T29	C0015237; Pharmaceutical Excipient; Biomedical or Dental Material
T30	CHEM 182 190	ALXN1007
#25	AnnotatorNotes T30	C3900167; Immunoglobulin, Anti-(human complement C5a) (human-mus musculus ALXN1007 heavy chain), Disulfide with Human-mus Musculus ALXN1007 Kappa-chain, Dimer; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T31	CHEM 408 411	aFL
T32	ANAT 565 569	piel
#26	AnnotatorNotes T32	C1123023; Skin; Body System | C1278993; Entire skin; Body System
T33	PROC 1279 1310	administración de la medicación
T34	ANAT 1356 1364	tiroides
#27	AnnotatorNotes T34	C0040132; Thyroid Gland; Body Part, Organ, or Organ Component | C1278878; Entire thyroid gland; Body Part, Organ, or Organ Component
T35	PROC 1417 1420	FT4
T36	CHEM 1526 1561	proteínas de inmunoglobulina humana
T37	CHEM 56 64	ALXN1007
#28	AnnotatorNotes T37	C3900167; Immunoglobulin, Anti-(human complement C5a) (human-mus musculus ALXN1007 heavy chain), Disulfide with Human-mus Musculus ALXN1007 Kappa-chain, Dimer; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T38	DISO 525 529	SAFL
#29	AnnotatorNotes T38	C0085278; Antiphospholipid Syndrome; Disease or Syndrome
T39	CHEM 546 549	aFL
T40	CHEM 688 691	aFL
T41	Date 13 17	2013
T42	LIVB 68 77	pacientes
#30	AnnotatorNotes T42	C0030705; Patients; Patient or Disabled Group
T44	LIVB 364 373	Pacientes
#31	AnnotatorNotes T44	C0030705; Patients; Patient or Disabled Group
T46	LIVB 617 624	Hombres
#32	AnnotatorNotes T46	C0025266; Male population group; Population Group
T47	LIVB 627 634	mujeres
#33	AnnotatorNotes T47	C0043210; Woman; Population Group
T48	Age 638 648	18-75 años
T49	LIVB 661 670	Pacientes
#34	AnnotatorNotes T49	C0030705; Patients; Patient or Disabled Group
T50	LIVB 742 751	pacientes
#35	AnnotatorNotes T50	C0030705; Patients; Patient or Disabled Group
T51	LIVB 934 943	pacientes
#36	AnnotatorNotes T51	C0030705; Patients; Patient or Disabled Group
T52	LIVB 1135 1144	pacientes
#37	AnnotatorNotes T52	C0030705; Patients; Patient or Disabled Group
T53	Duration 1240 1254	las 12 semanas
T55	LIVB 1462 1475	meningocócica
#38	AnnotatorNotes T55	C0027575; Neisseria meningitidis; Bacterium
T57	LIVB 1596 1603	mujeres
#39	AnnotatorNotes T57	C0043210; Woman; Population Group
T58	PHYS 1639 1648	lactancia
#40	AnnotatorNotes T58	C0006147; Breast Feeding; Organism Function | C0022925; Lactation; Organ or Tissue Function
T59	PHYS 1614 1625	embarazadas
#41	AnnotatorNotes T59	C0032961; Pregnancy; Organism Function
T43	Neg_cue 1099 1112	distintas del
T45	PROC 860 867	visitas
#42	AnnotatorNotes T45	C1512346; Patient Visit; Health Care Activity
A1	Assertion T16 Negated
A2	Status T21 History_of
A3	Status T27 History_of
#43	AnnotatorNotes T31	C0162595; Antiphospholipid Antibodies; Amino Acid, Peptide, or Protein · Immunologic Factor
#44	AnnotatorNotes T40	C0162595; Antiphospholipid Antibodies; Amino Acid, Peptide, or Protein · Immunologic Factor
#45	AnnotatorNotes T39	C0162595; Antiphospholipid Antibodies; Amino Acid, Peptide, or Protein · Immunologic Factor
#46	AnnotatorNotes T10	C0037299; Skin Ulcer; Disease or Syndrome 
#47	AnnotatorNotes T17	C2728549; acute venous thrombosis; Pathologic Function 
#48	AnnotatorNotes T33	C3469597; Administration of medication; Therapeutic or Preventive Procedure
#49	AnnotatorNotes T35	C0202225; T4 free measurement; Laboratory Procedure
#50	AnnotatorNotes T26	C0025303; Meningococcal Infections; Disease or Syndrome 
T54	Neg_cue 1476 1479	sin
T56	Observation 1480 1488	resolver
A4	Assertion T56 Negated
#51	AnnotatorNotes T56	C1709863; Recovered or Resolved; Finding
T60	Neg_cue 238 240	no
T61	Neg_cue 479 481	no
T62	CONC 482 520	cumplen los criterios de clasificación
A5	Assertion T62 Negated
T63	CONC 241 258	cumplen criterios
A6	Assertion T63 Negated
T64	Neg_cue 1365 1367	no
T65	Quantifier_or_Qualifier 1368 1378	controlado
A7	Assertion T65 Negated
R1	Negation Arg1:T54 Arg2:T56	
R2	Causes Arg1:T55 Arg2:T26	
R3	Negation Arg1:T64 Arg2:T65	
R4	Has_Quantifier_or_Qualifier Arg1:T21 Arg2:T65	
R5	Location_of Arg1:T34 Arg2:T21	
T66	Result_or_Value 1422 1430	anómalos
#52	AnnotatorNotes T66	C3648370; laboratory tests nonspecific abnormal findings; Finding (?)
R6	Has_Result_or_Value Arg1:T35 Arg2:T66	
R7	Has_Result_or_Value Arg1:T24 Arg2:T66	
R8	Has_Result_or_Value Arg1:T23 Arg2:T66	
R9	Has_Result_or_Value Arg1:T22 Arg2:T66	
R10	Before Arg1:T26 Arg2:T56	
R11	Causes Arg1:T36 Arg2:T27	
R12	Causes Arg1:T29 Arg2:T27	
R13	Causes Arg1:T28 Arg2:T27	
R14	Experiences Arg1:T57 Arg2:T59	
R15	Experiences Arg1:T57 Arg2:T58	
R16	Experiences Arg1:T42 Arg2:T37	
R17	Experiences Arg1:T42 Arg2:T1	
R18	Used_for Arg1:T30 Arg2:T3	
R19	Negation Arg1:T60 Arg2:T63	
R20	Overlap Arg1:T4 Arg2:T5	
R21	Experiences Arg1:T44 Arg2:T7	
R22	Experiences Arg1:T44 Arg2:T31	
T67	Quantifier_or_Qualifier 413 425	persistentes
#53	AnnotatorNotes T67	C0205322; Persistent; Temporal Concept
R23	Has_Quantifier_or_Qualifier Arg1:T7 Arg2:T67	
R24	Has_Quantifier_or_Qualifier Arg1:T31 Arg2:T67	
T68	Quantifier_or_Qualifier 430 440	al menos 1
R25	Has_Quantifier_or_Qualifier Arg1:T8 Arg2:T68	
R26	Negation Arg1:T61 Arg2:T62	
R27	Overlap Arg1:T8 Arg2:T38	
R28	Causes Arg1:T39 Arg2:T9	
R29	Location_of Arg1:T32 Arg2:T10	
R30	Overlap Arg1:T38 Arg2:T9	
R31	Overlap Arg1:T38 Arg2:T10	
R32	Overlap Arg1:T38 Arg2:T11	
R33	Experiences Arg1:T44 Arg2:T8	
R34	Experiences Arg1:T44 Arg2:T38	
R35	Experiences Arg1:T44 Arg2:T9	
R36	Experiences Arg1:T44 Arg2:T10	
R37	Experiences Arg1:T44 Arg2:T11	
R38	Has_Age Arg1:T47 Arg2:T48	
R39	Has_Age Arg1:T46 Arg2:T48	
R40	Experiences Arg1:T49 Arg2:T40	
T69	Quantifier_or_Qualifier 692 704	persistentes
#54	AnnotatorNotes T69	C0205322; Persistent; Temporal Concept
R41	Has_Quantifier_or_Qualifier Arg1:T40 Arg2:T69	
T70	Quantifier_or_Qualifier 707 733	clínicamente significativo
R42	Has_Quantifier_or_Qualifier Arg1:T40 Arg2:T70	
T71	Observation 764 774	dispuestos
#55	AnnotatorNotes T71	C0600109; Willing; Finding (?)
R43	Has_Quantifier_or_Qualifier Arg1:T50 Arg2:T71	
T72	Observation 781 788	capaces
#56	AnnotatorNotes T72	C1299581; Able (finding); Finding (?) | C1555472; Authorized; Finding (?)
R44	Overlap Arg1:T72 Arg2:T12	
R45	Overlap Arg1:T71 Arg2:T12	
R46	Has_Quantifier_or_Qualifier Arg1:T50 Arg2:T72	
T73	Observation 838 888	cumplir con todas las visitas y los procedimientos
R48	Before Arg1:T12 Arg2:T45	
R49	Before Arg1:T12 Arg2:T25	
T74	CONC 960 993	criterios de clasificación de ACR
R50	Negation Arg1:T43 Arg2:T16	
R51	Experiences Arg1:T51 Arg2:T13	
R52	Experiences Arg1:T51 Arg2:T14	
R53	Experiences Arg1:T51 Arg2:T15	
R54	Experiences Arg1:T51 Arg2:T16	
#57	AnnotatorNotes T15	C2895206; Systemic autoimmune disease; Disease or Syndrome
T75	Quantifier_or_Qualifier 1118 1126	primario
#58	AnnotatorNotes T75	C0205225; Primary; Qualitative Concept
R55	Has_Quantifier_or_Qualifier Arg1:T16 Arg2:T75	
R56	Experiences Arg1:T52 Arg2:T17	
R57	Experiences Arg1:T52 Arg2:T20	
R58	Location_of Arg1:T18 Arg2:T20	
R59	Overlap Arg1:T20 Arg2:T53	
R60	Overlap Arg1:T17 Arg2:T53	
R61	Before Arg1:T17 Arg2:T33	
R62	Before Arg1:T20 Arg2:T33	
T76	Quantifier_or_Qualifier 1271 1278	primera
#59	AnnotatorNotes T76	C0205435; First (number); Quantitative Concept
R63	Has_Quantifier_or_Qualifier Arg1:T33 Arg2:T76	
R64	Used_for Arg1:T19 Arg2:T33	
T77	Quantifier_or_Qualifier 1219 1229	importante
#60	AnnotatorNotes T77	C3898777; Important; Qualitative Concept
R65	Has_Quantifier_or_Qualifier Arg1:T20 Arg2:T77	
R66	Experiences Arg1:T52 Arg2:T33	
T78	PROC 1437 1446	selección
#61	AnnotatorNotes T78	C0242802; Patient Selection; Research Activity
R67	Overlap Arg1:T66 Arg2:T78	
R68	Overlap Arg1:T22 Arg2:T78	
R69	Overlap Arg1:T23 Arg2:T78	
R70	Overlap Arg1:T24 Arg2:T78	
R71	Overlap Arg1:T35 Arg2:T78	
#62	AnnotatorNotes T70	C5209294; Clinical relevance; Intellectual Product
A8	Experiencer T42 Patient
A9	Experiencer T44 Patient
A10	Experiencer T47 Patient
A11	Experiencer T46 Patient
A12	Experiencer T49 Patient
A13	Experiencer T50 Patient
A14	Experiencer T51 Patient
A15	Experiencer T52 Patient
A16	Experiencer T57 Patient
